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Abstract: 
Background: Sickle cell anaemia is prevalent in sub Saharan Africa. While α+-thalassaemia is known to modulate sickle cell 
anaemia, its magnitude and significance in Uganda have hitherto not been described. 
Objectives: To determine the prevalence of  α+thalassaemia among sickle cell anaemia patients in Mulago Hospital and to 
describe the clinical and laboratory findings in these patients. 
Methods: A cross sectional study was carried out on patients with sickle cell anaemia in Kampala. Dried blood spots were 
used to analyze for the deletional α+ thalassaemia using multiplex polymerase chain reaction. 
Results: Of  the 142 patients with sickle cell anaemia, 110 (77.5%) had the αα+thalassaemia deletion. The gene frequency 
of  (-α) was 0.425. Ninety one percent (100/110) of  those with α+thalassaemia were heterozygous (αα/α-). Amongst the 
patients older than 60 months, 15 (83.3%) of  those without αα+thalassaemia had significant hepatomegaly of  greater than 
4 cm compared to 36 (45.6%) of  those with α+thalassaemia (p=0.003). 
Conclusion: The gene frequency of  (-α) of  0.425 noted in this study is higher than that reported from many places in Af-
rica. Concurrent alpha thalassemia might be a protective trait against significant hepatomegaly in sickle cell anaemia patients 
more than 60 months of  age at Mulago hospital.
Keywords: Alpha thalassemia, sickle cell anaemia patients, Kampala, Uganda
DOI: http://dx.doi.org/10.4314/ahs.v15i2.48
Introduction
In the early 1960’s many adults with sickle cell anaemia 
(SCA) as well as those with mild disease were reported 
in Jamaica1.
Various factors, both genetic and environmental, are 
known to influence the clinical course and survival of  
patients with SCA. These factors do not only include 
the different haplotypes of  sickle cell and infections, 
but also the interaction of  sickle cell with alpha thalas-
saemia.
About 30% of  patients with SCA have concurrent de-
letional alpha thalassaemia (α+-thalassaemia)2. The het-
erozygotes have reduced  concentration of  HbS,  and 
HbS polymerization, less haemolysis, higher PCV, lower 
MCV and lower reticulocyte counts3-5. Alpha thalassae-
mia tends to ameliorate some but not all of  the clinical 
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features of  SCA6-8 .  It is widespread in Africa and is 
thought to reflect a survival advantage against severe 
malaria9-12. While there have been reports of  α+ -thal-
assaemia elsewhere in Africa, there is a dearth of  infor-
mation on its prevalence and interaction with sickle cell 
anaemia in Uganda13-15. 
 
In 1958 Raper described nine cases of  thalassaemia 
major amongst Ugandans of  Indian origin16. The main 
objective of  the current study was to determine the 
prevalence of  α+-thalassaemia among SCA patients at-
tending the sickle cell clinic at Mulago national referral 
hospital Kampala, using multiplex polymerase chain re-
action (MPCR), and to describe laboratory and clinical 
findings in these patients. This paper describes select 
clinical, and laboratory characteristics of  a cross-section 
of  children with SCA.
 
Methods 
The Sickle Cell Clinic at Mulago hospital has over 7000 
registered patients with SCA. This cross sectional study 
was conducted from December 1994 to January 1995. 
Sampling and recruitment
Assuming a prevalence of  α+-thalassaemia of  0.26 
based on a Kenyan study(15) and a precision of  6.3% 
at 95% confidence intervals, every third patient with a 
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confirmed diagnosis of  SCA, was enrolled and data was 
obtained from 142 children aged up to 19 years. 
Basic demographic, anthropometric, and clinical data 
were collected. Those who were very sick and those 
who had had a blood transfusion in the previous three 
months were excluded.
Written informed consent was obtained from the par-
ent or caretaker of  each child, and ethical clearance was 
obtained from the Department of  Paediatrics and Child 
Health, Makerere University and the National Council 
of  Science and Technology. .
 
Laboratory data
Haematological data was obtained for all children using 
a haematology analyser (Beckman Coulter Inc, AcT Mi-
ami FL 33196-2500 USA). Haemoglobin was analysed 
by electrophoresis on cellulose acetate gels (Helena 
Laboratories UK limited) at pH8.6 voltage 200v. Mi-
gration time was at least 30 minutes, and the strips were 
labeled using serum as a marker.  Dried blood spots for 
the DNA analysis were kept at a room temperature for 
at least four hours, stored at 4ºC and later transported 
to the Clinical Biochemistry Laboratory –– Evanston 
Hospital USA, where DNA analysis to type for α-glo-
bin genotype was performed using Multiplex Polymer-
ase Chain Reaction (MPCR) techniques17. 
Thick and thin blood smears were analysed for malar-
ia parasites and peripheral blood picture and were per-
formed on all study participants. 
 
Data management and statistical analysis
Epi-info software version 6 was used for data-entry and 
analysis. The sample was described using frequency dis-
tributions, while tables and graphs were used to illus-
trate variables.
Mean values for continuous variables were reported as 
±2 standards deviations.
The chi squared test was used to determine associations 
between ‘exposure’ and the main outcome variables.
 
Results
A total of  142 patients with SCA were recruited of  
whom 67 (47.2%) were males.
Alpha -thalassaemia status  
The gene frequency for (-oc) deletion was 0.425.One 
hundred and ten participants (77.5%) had α+thalassae-
mia, while 32 participants (22.5%) had a normal com-
ponent of  alpha genes. Of  the 110 participants with 
α+thalassaemia, 100(90.9%) were heterozygotes (ococ/
oc-) while 10 (9.0 %) were homozygotes (oc-/oc-).  The 
majority of  the participants with α+thalassaemia were 
in the age group 61-120 months. Among participants 
who were more than 120 months the majority 44/55 
(80%) were from the α+thalassaemia group.
The Baganda were the predominant ethnic group ac-
counting for 76.1% (108/142), followed by the Basoga 
with 8.5 %.( 12/142).
The age range of  the participants was 5.9 months to 
19 years, with a mean age of  8.7 years and a median of  
8.2 years. The age group 61-120 months, had the largest 
number of  study participants (n=43). Fig 1
 Figure 1.  Age distribution by α+ thalassaemia (α+thal) status 
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Age at initial diagnosis
Figure 2 shows the relationship between age at initial 
diagnosis of  SCA and α+thalassaemia status. 
Participants were grouped according to age at which a 
diagnosis of  sickle cell anemia was first made.  In about 
half  the cases ((51.4%) (73/142)) , the disease present-
ed during  the first 12 months of  life, with only 21% 
(30/142 ) of  all the  participants first presenting after 
the age of  5 years, and by the age of  five years 79% had 
had the diagnosis of  SCA made.
Alpha thalassaemia did not seem to affect the age at 
which a diagnosis of  SCA was first made (P=0.39).
Of  the 110 participants with α+thalassaemia, 26 
(23.6%) had the diagnosis of  SCA made after 5 years 
in comparison to only 4 (12.5% in the non-α+thalas-
saemia group.
Clinical history and physical findings of  the participants 
is presented in Table 1and 2. At the time of  the study, 
107 (75.3%) of  all the participants had had a duration 
of  symptoms of  SCA for less than 1 year. 
Table 1: History and symptoms of sickle cell patients with or without α+thalassaemia 
(α+thal).   
  
History/Symptom α+thal (n=110) Non-α+thal 
(n=32) 
P value OR (CI) 
Hand and foot 
syndrome at initial 
presentation  














0.88 (0.36 – 2.16) 












0.63 (0.20 – 2.06) 
Hand foot 
syndrome in 











0.75 (0.29 – 1.94) 
Painful limbs in 
the last one year 
           
 
101 (92.7%) 







2.59 (0.74 – 8.94) 
History of 
hospitalisation  










0.75 (0.24 – 2.18) 
 
Blood  transfusion 
           
 
49 (44.5%) 







0.62 (0.26 – 1.48) 
 
OR = Odds Ratio        CI = Confidence Intervals 
Table 2: 
Findings on physical examination of sickle cell patients and α+thalassaemia (α+thal) 
status 
Clinical findings α+thal Non-α+thal   P– 
Value  
OR (CI) 
Height for age 
         < 2SD 
         >2SD 
 
   
14 (46.5%) 







0.79 (0.24 – 2.77) 
Weight for age 
               < 2SD 











0.86 (0.23 – 3.44) 
Weight for 
height 
                > 2SD 













0.57 (0.08 – 4.70) 
Dactylitis in  
Less than 60 
mths of age  
   Yes  


















1.480.16 – 34.66) 
Hepatomegaly in  
Greater  than 60 
mths of age  
         ≤ 4cms 


















6.20 (1.66 – 27.31) 
Persistent 
splenomegaly 
in  >more than 
60 mths age 
     Yes  






















1.53 (0.63 – 3.78) 
OR = Odds Ratio. CI= 95% confidence interval. Apart from hepatomegaly > 4cm in α+thal 
subjects more than 60months of age, α+thal status did not influence the physical findings. 
 
 
A history of  leg ulceration was available in only 3 par-
ticipants (ages 12, 16 and 17 years) and only 1 partici-
pant (from the non-α+thalassaemia) was found to have 
chronic leg ulceration.
About half  of  the participants 55.4% (61/110) in 
the α+thalassaemia group and 43.7 % (14/32) in the 
non-α+thalassaemia group had no history of  blood 
transfusion.
More than half  the patients 55.6% (79/142) had no 
palpable spleen and the frequency of  persistent sple-
nomegaly in patients above the age of  60 months was 
similar in both α+thalassaemia and non-α+thalassae-
mia groups with  62% (49/79) and 61.1% (11/18)in the 
α+thalassaemia and non-α+thalassaemia group respec-
tively (P= 0.94).
 
Virtually all participants ((99.3%) (141/142)) had a he-
patomegaly (1-15cm).  Amongst the participants old-
er than 60 months, 83.3% (15) of  those without the 
α+thalassaemia deletion had a hepatomegaly of  greater 
than 4 cm compared to 45.6% (36) of  those with the 
α+thalassaemia (p=0.003). Table 2
The haematological indices did not differ between the 
two groups. Table 3
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                  α+thal status did not influence the haematological indices.  
Only 20 (14.3%) of  140 participants had malarial par-
asites detected in their blood.  All of  them had Plas-
modium falciprarum 1-10 parasites per 100 thick film 
fields.  Other than Plasmodium falciprarum no other 
malaria parasites were detected and only 3 of  these par-
ticipants were free of  any symptoms at the time.
The commonest peripheral blood film report docu-
mented was hypochromia with poikilocytosis and in all 
participants, sickle cells were detected.  Sixty three par-
ticipants (44.4%) had marked hypochromia, 64 (45.0%) 
had moderate hypocromia, while 14 (9.8%) had mild 
hypochromia. Only one patient was reported to have a 
normocytic peripheral blood picture.
Discussion
The Baganda were the predominant ethnic group 76.1% 
(108/142) reflecting the general ethnic composition of  
patients attending clinics and general wards in Mulago 
hospital.  Ndugwa and Kanyike  in their analysis of  pa-
tient’s attendance in the same sickle cell clinic reported 
a similar percentage of  81%18. The Baganda have been 
previously reported to have a high incidence of  SCA 
with a carrier rate of  17%.19  
A gene frequency of  (-α) of  0.425 recorded in this 
study is probably one of   the highest gene frequencies 
recorded in sub Saharan Africa and comparable to that 
of  Congo Brazzaville where Mouele, et al  recorded a 
gene frequency of   0.45 among patients with  SCA, and 
that recorded by  Williams et al on the Kenyan coast12,20. 
Other studies including those of  Ojwang et al in Kenya 
and Falusi et al in Nigeria have recorded frequencies of  
0.26 and 0.24 respectively15,21.
 
The high (-α) gene frequency in the current study com-
pared with others from elsewhere in Africa supports the 
suggestion by other investigators  including Moule that 
there seems to be  a gradient  for the (-α) across Africa, 
the  gene frequency being highest  in equatorial Africa 
and  lowest in both Northern and Southern Africa12. 
 
On the other hand this high gene frequency might be 
attributed to the method used to detect the α+thalas-
saemia deletion.  Unlike the MPCR technique used in 
the current study17, earlier tests were based on imprecise 
globin synthesis techniques that they could not clear-
ly differentiate between α+thalassaemia homozygotes, 
heterozygotes and normal individuals22,23.  The question 
that inevitably arises is that of  the gene frequency in 
the general population versus that in patients with SCA. 
Does the HbS gene have an affinity for α+-thalassaemia 
and will the frequency of  α+-thalassaemia be higher 
among patients with SCA than in the general popula-
tion? 
Pagnier et al  noted that in Senegal, the frequency of  
α+thalassaemia was the same in SCA patients as in non 
SCA  individuals (-α=0.1) whilst in Benin, and Upper 
Volta the gene frequency in HbSS individuals of  0.27 
was almost twice the gene frequency in the non SCA 
individuals (0.14)24. In Congo Brazzaville it was noted 
that the gene frequency for the deletional -oc3.7 was 
0.40, 0.36, 0.44 and 0.45 in newborns, non-SCA  adults, 
sickle trait and individuals with SCA respectively12 
To investigate whether α+thalassaemia status influenc-
es age at initial presentation of  symptoms of  SCA, we 
used “age at initial diagnosis” as a surrogate marker in 
the analysis. In spite of  this approximation and know-
ing well that there may have been a variable sequential 
gap between first symptoms and when a diagnosis of  
SCA was made, it is noteworthy that by 1 year about 
half  of  the participants ((73/142) (51.4 %)), and by 5 
years (112/142 (78.9%) had symptoms of  SCA. 
 
Although half  of  the patients presented with symp-
toms of  SCA during infancy, there were only 4 patients 
with SCA below one year in this study.  After infan-
cy, the overall number of  patients rose sharply up to 
10 years. These results are comparable to those of  an 
observational study among SCA children in Kenya25. 
That many children die in infancy before a diagnosis of  
SCA is made and that the older ones that are seen are 
a reflection of  those who have favorable genetic or en-
vironmental factors for survival beyond infancy, might 
explain this trend.
There were fewer participants over the age of  10 years. 
It was observed that for the patients who were more 
than 15 years of  age, the proportion of  individuals with 
α+thalassaemia was greater than that of  SCA individ-
uals without α+thalassaemia. Whether the presence of  
α+thalassaemia improves survival in SCA patients is 
not certain.
 
There have been several studies on the effect of  α+thal-
assaemia on survival of  patients with SCA but the re-
sults are not cosmopolitan. Mears et al has suggested 
that α+thalassaemia is related to prolonged survival 
while Higgs, Miller and Mouele5,12,26,27 did not make the 
same conclusions. This lack of  precision could be partly 
due to the small number of  patients studied as well as 
nonsystematic and structured collection of  clinical data 
in the different studies. In order to settle this question 
one would have to study a large group of  patients with 
SCA in the older age group and determine the num-
ber of  those with and without α+thalassaemia but this 
would have to be done after controlling for other ge-
netic and environmental factors that profoundly affect 
child survival.
There was no statistically significant correlation be-
tween α+thalassaemia status and a history of  painful 
limbs in the last one year, and a history or presence of  
or leg ulceration was virtually missing in this population 
of  SCA patients and so were Vaso-occlusive events that 
are highly dependent on PCV, such as stroke.  
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